Bioventus Receives Consensus Buy Rating from Analysts

Analysts see upside potential for the medical device company's stock.

Apr. 6, 2026 at 8:12am

Got story updates? Submit your updates here. ›

Shares of Bioventus Inc. (NASDAQ:BVS) have received an average rating of "Buy" from the five analysts covering the stock, according to Marketbeat Ratings. One analyst has a hold rating, three have buy ratings, and one has a strong buy rating on the stock, with an average 12-month price target of $14.

Why it matters

Bioventus is a global medical device company focused on orthobiologic solutions, which are non-surgical therapies designed to address bone healing, osteoarthritis pain management, and soft tissue repair. A consensus buy rating from analysts suggests they see potential upside in the company's stock as it continues to develop and commercialize its portfolio of products.

The details

The analysts' ratings and price targets reflect their optimism about Bioventus' business prospects. Several firms, including Barrington Research, Craig Hallum, and Cantor Fitzgerald, have issued positive ratings and increased their price targets on the stock in recent months.

  • Bioventus reported its latest quarterly earnings on March 5, 2026.
  • The company set its fiscal year 2026 earnings guidance on March 5, 2026.

The players

Bioventus Inc.

A global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Bioventus can meet or exceed its fiscal year 2026 earnings guidance as the company continues to grow its portfolio of orthobiologic products.

The takeaway

The consensus buy rating from analysts suggests they see Bioventus as a promising investment opportunity in the medical device space, with the company's focus on innovative orthobiologic solutions positioning it for potential growth.